Cambridge Healthtech Institute’s Seventh Annual, Coverage and Reimbursement for Advanced Diagnostics – Latest Developments in the Dx Reimbursement Landscape. Ammar Qadan, Vice President, Global Market Access, Illumina and Roger Longman, CEO, RealEndpoints present: Addressing the Biggest Commercial Problem in Diagnostics

To explore new models of payment and benefit designs for high-investment medications, the AMCP convened a stakeholder conference in Baltimore Maryland on July 24 and 25, 2018. Health care leaders representing health plans, integrated delivery systems, pharmacy benefit managers, employers, national professional associations, the federal government, and biopharmaceutical companies participated in the forum.

ISPOR is the leading global scientific and educational organization for health economics and outcomes research (HEOR) and its use in decision making to improve health. Our annual conference includes over 5,000 attendess from across the industry.

We’ve seen an explosion of value-based deals: from 10 in 2015-2016 to 25 from 2017 to Q1 2018 (and we’re on pace for 30+ this year), according to the Real Endpoints database. But we’ve also had the time to see which deals from 2015-16 haven’t worked — and why. We will take a candid look at what’s worked and what hasn’t worked in value-based agreements — as well as preview the drugs coming to market in 2018 that could benefit from value-based agreements.

Value & Pricing Redux – Does the Song Remain the Same?

Asembia’s Annual Specialty Pharmacy Summit will return to Wynn & Encore Las Vegas from April 29 through May 2, 2018. The Summit welcomes thousands of industry executives and professionals. Agenda highlights include business workshops, educational seminars, exhibits, and live continuing education credits, along with numerous networking and social events.